Cell Therapeutics Inc (NASDAQ:CTIC)

3.02
Real-Time Quote
 -0.05 / -1.63%
Today’s Change
0.97
Today|||52-Week Range
4.25
+58.12%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$477.3M

Company Description

Cell Therapeutics, Inc. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Its products include Pixuvri, OPAXIO, Brostallicin and Bisplatinates. Pixuvri is a novel anthracycline derivative used for the treatment of hematologic malignancies and solid tumors. Pixuvri was studied in its EXTEND or PIX301, clinical trial, which is the first randomized, controlled, phase III single-agent clinical trial of Pixuvri for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma or NHL, who received two or more prior therapies and who were sensitive to treatment with anthracyclines. OPAXIO is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. Brostallicin is a new class of cancer drug-a synthetic DNA minor groove binding agent with a unique mechanism of action. Brostallicin is currently in a phase II trial for the treatment of metastatic triple-negative breast cancer. Bisplatinates is a platinum-based chemotherapy drug used to treat a wide variety of cancers. The company's technologies include Polyglutamate Drug Delivery, Genetic Polymer and Context of vulnerability. The Polyglutamate Drug Delivery technology open the way to the selective delivery of cancer therapies to tumor tissue, potentially reducing the toxic side effects of widely used and well-characterized therapies. The Genetic Polymer technology supports the need for new rDNA-derived protein-based drugs by potentially extending plasma half-life. Cell Therapeutics was founded by James A. Bianco, Jack W. Singer and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Contact Information

Cell Therapeutics, Inc.
3101 Western Avenue
Seattle Washington 98121
P:(206) 282-7100
Investor Relations:
(206) 272-4343

Employees

Shareholders

Other institutional7.89%
Individual stakeholders16.51%
Mutual fund holders13.34%

Top Executives

James A. BiancoPresident, Chief Executive Officer & Director
Lou A. BiancoExecutive Vice President-Finance & Administration
Jack W. SingerDirector & EVP-Global Medical Affairs
Matthew J. PlunkettExecutive Vice President-Corporate Development
Monique GreerSVP-Investor Relations & Corporate Communications

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.